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THE 3 - methylchloanthrene - induced
murine sarcoma, Meth A, is amongst the
most strongly immunogenic ofthe chemic-
ally induced experimental tumours, so
that it has been widely used as a model for
the study of immune rejection responses
and for the isolation and characterization
of tumour-associated antigens (Law &
Appella, 1975; Law et al., 1978). Purified
plasma-membrane preparations have fre-
quently been used as a source of immuno-
genic material (McCollester, 1970; Natori
et al., 1977) though more recently the
soluble intracytoplasmic protein fraction
of tumour homogenates was found to be a
source of abundant antigen (Dubois et al.,
1980).
Previous studies have demonstrated
that the protein-cross-linking agent,
glutaraldehyde, fails to modify the im-
munogenicity of Meth A sarcoma cells
(Price et al., 1979) and subsequent tests
have shown that after treatment of cells
with glutaraldehyde at concentrations as
high as 0.5o/, their capacity to induce
immunoprotection against a challenge of
viable tumour cells was unimpaired. The
present report extends these original
observations by analysing the immuno-
genicity of Meth A subeellular fractions,
rather than cells, after treatment with
glutaraldehyde. This approach was
adopted to optimise conditions for the
reaction of both soluble intracellular and
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membrane-associated antigenswithglutar-
aldehyde. The results from immunization
of mice with various Meth A sarcoma sub-
cellular preparations pretreated with
0*01% glutaraldehyde are summarized in
the Table (Expts 2 to 7). The results may
be compared with those obtained con-
currently using glutaraldehyde-treated
tumour cells in which no modification of
immunogenicity was detected at any
immunizing dose (Expt 1). The concentra-
tion of glutaraldehyde selected (0.01%)
represents a 1mM solution, which is com-
parable to that required for the conjuga-
tion of soluble proteins (e.g. enzymes to
antibodies, Avrameas et al., 1978) but
below that used for the preparation of
insoluble polymerized protein gels
(Ternynk & Avrameas, 1976). This con-
centration is also commonly used for the
fixation of cells to be used in radioisotopic
antiglobulin assays, with the retention of
activity of serologically defined cell-
surface antigens (Al-Sheikly et al., 1980).
As shown in the Table, treatment of
Meth A plasma membranes or Meth A
cytosol with glutaraldehyde did not re-
duce their capacity to confer resistance to
tumour-cell challenge (Expts 2 & 3).
Comparable protection was obtained with
untreated or glutaraldehyde-treated
plasma membranes or cytosol, irrespective
of the doses of immunizing material (data
not in Table). For example, the tumourGLUTARALDEHYDE TREATMENT OF METH A CELLS
TABLE.-Immunization with glutaraldehyde-treated Meth A sarcoma cells and subcellular
preparations
Tumour takes in
Mice immunized with
fraction pretreated witht
Expt Immunizing fraction* Buffer
1 106 JR cells 2/16
(P< 0 001)t
105 IR cells 3/16
(P< 0-001)
104 IR cells 4/8
(N.S.)
2 Plasma membranes § (8 mice received 0/16
320 jig/dose; 8, 32 ,ug/dose) (P< 0-001)
3 Cytosoll) (8 received 120 Htg/dose; 2/16
8, 12 jig/dose) (P=0-014)
4 106 fixed cells (- 70'C--37°C) x 3.
sonicated
5 106 fixed eells (-70'C-.370C) x 3,
sonicated, extracted with 1% NP 40,
sonicated
6 Nucleill (8 received 2 x 106 nuclei/
dose; 8, 2 x 105 nuclei/dose)
7 BALB/c serum (0-2 ml, 1/4 dilution)
Meth A bearer serum (0-2 ml,
1/4 dilution)
Meth A soluble ascitic fluid¶ (0-2 ml)
Glutar- Untreated
aldehyde control
0-01% (v/v) mice
4/16
(P <0-001)
3/16 192 (P<0-001) 19/24
4/8
(N.S.) J
3/16
(P =0.037)
1/16
(P=0 004)
0/8
(P=0-012)
0/8
(P=0-012)
3/16 7/16
(P=0-012) (N.S.)
8/8
(N.S.)
7/8
(N.S.)
7/8
(N.S.)
{ 12/24
}
6/8
8/8
* BALB/c mice received 2 injections of the immunizing subeellular fractions, with an interval of 10 days.
For immunization with irradiated (IR) cells, a single inoculum was injected per mouse. All animals were
challenged s.c. with viable Meth A sarcoma cells 10 days after the final injection, using 104 cells in Expts 1-6
and 2 x 104 cells in Expt 7.
t Immunizing fractions were treated with 0-01% glutaraldehyde for 30 min, after which membrane
preparations, cells and nuclei were washed by centrifugation and resuspended in PBS, whilst the treated
cytosol was dialysed against PBS at 4°C.
t Data analysed for statistical significance of comparison with controls, using the Fisher Exact Test.
N.S. =Not significant.
§ Prepared according to Rogers et al. (1980).
Prepared according to Price & Baldwin (1974).
Centrifuged at 100,000 g for 60 min before injection.
incidence in mice immunized with 32 jug
of treated plasma membranes (1/8) or
12 .g of treated cytosol (1/8) was equiva-
lent to that in mice receiving 320 ug of
treated plasma membrane (2/8) or 120 /tg
of treated cytosol (0/8). Similarly, even
cells fixed with 0-01% glutaraldehyde,
freeze-thawed x 3 and sonicated (Expt 4)
and in Expt 5, also further extracted with
1% NP40 and re-sonicated, were immuno-
genic such that all treated mice survived
the challenge of 104 viable Meth A cells.
Immunization of mice with 0 01% glutar-
aldehyde-treated nuclei or untreated
nuclei failed to reveal any reliable effects
of fixation, with the exception that un-
treated nuclei were immunoprotective
(Expt 6). Since the Meth A antigen
appeared to be ubiquitous in these various
subcellular preparations, 2 other frac-
tions were examined. Meth A tumour-
bearer serum and ascitic fluid were both
collected at terminal stages of tumour
growth and evaluated for their immuno-
genicity. As shown in Expt 7, the tumour
yield from challenge in mice receiving
585586 Mi. R. PRICE, D. GERLIER AND L. WV. LAW
these 2 preparations was equivalent to
that in untreated mice or in mice treated
with normal mouse serum.
It is concluded from the data sum-
marized in the Table that treatment of
Meth A cells or subcellular fractions with
0 010% glutaraldehyde failed to modify the
immunogenicity of these preparations. In
order to analyse the specificity ofimmuno-
protection conferred on treated mice,
those animals which survived the chal-
lenge of Meth A sarcoma cells were re-
challenged with 5 x 104 mKSA sarcoma
cells, when 9000 of mice succumbed to
tumour growth. No differences were re-
corded in the rate of growth or tumour
incidence between groups.
The present findings are in accord with
the current view that the Meth A sarcoma-
associated rejection antigen is a soluble
protein which is expressed intracellularly
(Dubois et al., 1980). The antigen must
show some expression at the cell surface,
to initiate immune responses and to func-
tion as a target for immunological recog-
nition and attack, though how many
determinants are required to participate
in such reactions is unknown. It is possible
that only a few copies at the cell surface
are sufficient, and/or that their expression
at the surface is transient, occurring only
during export and secretion. Ifthe antigen
is in fact secreted, then it is rapidly in-
activated, since soluble ascitic fluid and
tumour-bearer serum were clearly non-
immunogenic in the present investigation
(Expt 7). The finding that Meth A nuclei
were immunogenic is open to several
interpretations. Is the Meth A antigen
expressed on nuclei or on nuclear mem-
branes? Alternatively, does their immuno-
genicity reflect adsorption of soluble cyto-
plasmic antigen? The present results
emphasize that there is a need for caution
in interpreting data in terms of antigen
localization following subcellular fraction-
ation oftumour homogenates.
The stability and resistance ofthe Meth
A antigen to glutaraldehyde is remarkable.
The results do not support the contention
that the immunogenicity oftreated cells is
attributable to the slow release of non-
fixed soluble cytoplasmic antigen. Vigor-
ous extraction of fixed cells or direct
treatment ofplasma membranes or cytosol
does not modify the immunogenic charac-
ter of these preparations, suggesting that
glutaraldehyde-treated antigen per se is
immunogenic, and that host processing
leading to the induction of immunity is
not impaired by the presentation of anti-
gen chemically modified with glutaralde-
hyde. Further studies are required to
determine how, in the induction of
immunity to the Meth A sarcoma, the
immunized host may process the antigen
when it is presented on a highly polymer-
ized substrate (e.g. the treated cell).
This study was supported in part by funds
awarded to M. R. Price by the Cancer Research
Campaign.
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